GO
Loading...

Eli Lilly and Co

More

  • Early movers: GM, CAT, CMCSA, MMM, LUV, T & more Thursday, 23 Oct 2014 | 8:27 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Lilly profit plunges as cheaper generics take toll Thursday, 23 Oct 2014 | 7:54 AM ET

    Eli Lilly earnings plunged, hurt by special charges and generic competition for its Cymbalta depression drug, but it affirmed its full-year forecast.

  • Oct 23- Eli Lilly and Co said its quarterly earnings plunged 58 percent, hurt by special charges and generic competition for its Cymbalta depression drug, but it affirmed its earlier full-year profit forecast. The U.S. drugmaker on Thursday said it had earned $501 million, or 47 cents per share, in the third quarter. Sales fell 16 percent to $4.88 billion, but topped...

  • Lilly profit plunges as cheaper generics take toll Thursday, 23 Oct 2014 | 6:50 AM ET

    Oct 23- Eli Lilly and Co said its quarterly earnings plunged 58 percent, hurt by special charges and generic competition for its Cymbalta depression drug, but it affirmed its earlier full-year profit forecast. The U.S. drugmaker on Thursday said it had earned $501 million, or 47 cents per share, in the third quarter. Sales fell 16 percent to $4.88 billion, but topped...

  • Oct 16- The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said. There were no major safety issues associated with secukinumab, according to the review posted on the FDA website on Thursday- four days before a panel of outside advisers is...

  • *Endo offers $33.25/ share for Auxilium. Oct 9- Endo International Plc brought a successful end to its month-long pursuit of Auxilium Pharmaceuticals Inc, with the smaller rival choosing a sweetened offer over its agreement to buy Canadian eye-drug maker QLT Inc.. "Endo recognizes the value inherent to Xiaflex, given the drug's potential in multiple additional...

  • Oct 6- Alcobra Ltd lost more than half its market value after it said its drug to treat adult attention deficit disorder met the main goals of a late-stage trial- but only after excluding data from patients who reacted positively to a placebo. Alcobra's stock was the biggest loser on the Nasdaq as the results also made it less likely the company would be bought.

  • While Lilly's shares hardly budged on the news, the ADRs of Israel- based XTL Biopharmaceuticals Inc, which is developing its own lupus treatment, nearly tripled to $5.00. About 1.5 million people in the United States are estimated to suffer from lupus, according to the U.S. Centers of Disease Control and Prevention. The U.S. Food and Drug Administration approved...

  • *No EU concerns about Eli Lilly, Novartis deal. In contrast, U.S. drugmaker Eli Lilly's proposed $5.4 billion takeover of Swiss peer Novartis's animal health business triggered no such worries and will be cleared unconditionally, the sources said. Eli Lilly is buying the Novartis unit to strengthen and diversify its Elanco unit.

  • Eli Lilly to drop development of lupus drug Thursday, 2 Oct 2014 | 8:57 AM ET

    Oct 2- Eli Lilly and Co said it would discontinue the development of its lupus drug as the treatment was not found to be effective enough in two late-stage trials. The decision will result in a charge of about 4- 5 cents per share in the third quarter, the company said. Eli Lilly said the decision was not because of any safety concerns.

  • Waksal brothers reunite in ImClone 2.0 Thursday, 25 Sep 2014 | 1:31 PM ET
    Sam Waksal of Kadmon Pharmaceuticals

    Kadmon, the drug company founded by Sam Waksal of ImClone and Martha Stewart fame, is starting to look more and more like its founder's last company.

  • A blast from Martha's past: Waksal plans new IPO Wednesday, 24 Sep 2014 | 7:31 AM ET
    Former ImClone CEO Sam Waksal leaves federal court in New York, June 10, 2003.

    Banned ImClone founder Sam Waksal's new biotech company, Kadmon, has plans to go public. The company aims to file with the SEC by the end of this year.

  • Sept 17- Testosterone replacement therapies should be reserved for men with specific medical conditions that impair function of the testicles, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The FDA is not obliged to follow the advice of its advisory panels but typically does so.

  • For Roche CEO, celebrating failure is key to success Wednesday, 17 Sep 2014 | 8:06 AM ET

    LONDON, Sept 17- Roche Chief Executive Severin Schwan likes to crack open the champagne with his drug research teams at the end of a big project- especially when they fail.

  • NEW YORK, Sept 16- U.S. stocks were set to open lower on Tuesday with traders positioning for a Federal Reserve meeting expected to provide clues on the short term direction of U.S. interest rates.

  • Early movers: HSY, SHLD, BX, BA, LMNT, BABA & more Tuesday, 16 Sep 2014 | 7:35 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • US STOCKS-Futures dip ahead of data, Fed eyed Tuesday, 16 Sep 2014 | 7:33 AM ET

    *The Labor Department's producer price index, due at 8:30 a.m. EDT, is expected to have risen 0.1 percent in August, the same as in July.

  • *Lilly to partner on AstraZeneca's BACE inhibitor drug. LONDON, Sept 16- AstraZeneca has signed a partnership deal with U.S. rival Eli Lilly that could earn the British company up to $500 million if a promising- but risky- experimental Alzheimer's drug proves successful.

  • Midday movers: eBay, Sprint, Yahoo & more Friday, 12 Sep 2014 | 12:20 PM ET

    Take a look at some of Friday's midday movers:

  • Sept 12- Eli Lilly and Co's Cyramza stomach-cancer drug prolonged survival of patients with advanced colon cancer in a late-stage study, the U.S. drugmaker said on Friday. The 1,000- patient global study, called RAISE, involved patients who had previously failed to adequately benefit from Roche Holding AG's Avastin and other standard treatments.